EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis …

…, AI Estrella, AN Olivieri, MG Alpigiani… - Annals of the …, 2010 - ard.bmj.com
Objectives To validate the previously proposed classification criteria for Henoch–Schönlein
purpura (HSP), childhood polyarteritis nodosa (c-PAN), c-Wegener granulomatosis (c-WG) …

Pattern of interleukin‐1β secretion in response to lipopolysaccharide and ATP before and after interleukin‐1 blockade in patients with CIAS1 mutations

…, A Buoncompagni, MG Alpigiani… - … : Official Journal of …, 2007 - Wiley Online Library
… Maria Giannina Alpigiani … Patients were treated with IL-1Ra (anakinra) at a starting
dosage of 1–2 mg/kg/day, delivered subcutaneously (maximum daily dose 100 mg). …

Long‐term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients

…, F Falcini, M Alessio, MG Alpigiani… - Arthritis Care & …, 2010 - Wiley Online Library
Longâ•’term outcome and prognostic factors of juvenile dermatomyositis: A multinational,
multicenter study of 490 patients Page 1 Long-Term Outcome and Prognostic Factors of …

Ocular involvement in children with localised scleroderma: a multi-centre study

…, G Higgins, F Vittadello, MG Alpigiani… - British journal of …, 2007 - bjo.bmj.com
Background: Most of the available documentation in the literature on ocular involvement in
localised scleroderma (LS) are descriptions of single cases in adult patients. This article …

Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus

…, L Breda, A Pistorio, S Grassi, MG Alpigiani… - Lupus, 2006 - journals.sagepub.com
Our objective was to investigate the pattern of damage accumulation in patients with juvenile-onset
systemic lupus erythematosus (JSLE) and the relationship between damage accrual, …

[PDF][PDF] Pediatric rheumatology-Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis

…, E Cortis, L Lepore, MG Alpigiani… - Clinical & …, 2008 - academia.edu
… Susan Nielsen, MD; Nicolino Ruperto, MD, MPH; Valeria Gerloni, MD;Gabriele Simonini,
MD;Elisabetta Cortis, MD; Loredana Lepore, MD; Maria Giannina Alpigiani, MD; Francesco …

The shrunken, bright cerebellum: a characteristic MRI finding in congenital disorders of glycosylation type 1a

…, M Severino, MG Alpigiani… - American journal …, 2012 - Am Soc Neuroradiology
CDG-1a is an early-onset neurodegenerative disease with selective hindbrain involvement
and highly variable clinical presentation. We retrospectively reviewed the clinical records …

[HTML][HTML] Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

…, A De Fanti, V Muratore, MG Alpigiani… - Pediatric …, 2016 - Springer
Background Data from routine clinical practice are needed to further define the efficacy and
safety of biologic medications in children with juvenile idiopathic arthritis (JIA). The aim of …

Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis

…, J Walsh, IC Penades, MG Alpigiani… - Annals of the …, 2008 - ard.bmj.com
… standard dose of MTX (10 mg/m 2 /week) for 6 months, and then the non-responders were
randomised to receive either intermediate (15 mg/m 2 /week) or high doses (30 mg/m 2 /week…

Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study.

…, MO Hilário, MG Alpigiani… - Clinical and …, 2006 - europepmc.org
… CSA was started at a mean of 5.8 years after disease onset and was given at a mean dose
of 3.4 mg/kg/day. The drug was administered in combination with MTX in 61% and along with …